Zim Laboratories (NSE:ZIMLAB) disclosed, via an exchange filing dated 06 August 2026, that its Board of Directors approved unaudited consolidated and standalone financial results for the quarter ended 30 June 2026, with consolidated revenue from operations at Rs 9,417.85 lakh and a consolidated net loss after tax of Rs 401.70 lakh.
Key Highlights
- Consolidated revenue from operations for Q1 FY27 rose to Rs 9,417.85 lakh, compared with Rs 7,175.61 lakh in Q1 FY26, representing year-on-year growth of approximately 31.2%.
- The consolidated net loss after tax widened to Rs 401.70 lakh in Q1 FY27 from a net loss of Rs 187.49 lakh in the same quarter of the previous year.
- Total consolidated expenses for Q1 FY27 were Rs 10,074.38 lakh, exceeding total income of Rs 9,517.08 lakh and resulting in a pre-tax loss of Rs 557.30 lakh.
- Deloitte Haskins and Sells LLP issued a limited review report on both the consolidated and standalone results, with no material misstatements noted.
About the Company
Zim Laboratories Limited (NSE:ZIMLAB), headquartered in Nagpur, Maharashtra, is a pharmaceutical company incorporated in 1984 under CIN L99999MH1984PLC032172. The company manufactures drug delivery systems and finished dosage forms at its MIDC facility in Kalmeshwar, Nagpur. Its international footprint spans subsidiaries in Sharjah, Latvia, Australia, and Dubai, serving regulated and semi-regulated pharmaceutical markets across multiple geographies.
Announcement in Detail
The Board of Directors convened on 06 August 2026, with the meeting commencing at 10:30 a.m. and concluding at 01:50 p.m. IST. Pursuant to Regulation 30 and Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015, the board approved unaudited consolidated and standalone financial results for Q1 FY27, covering the quarter ended 30 June 2026.
On a consolidated basis, cost of materials consumed stood at Rs 4,381.61 lakh, employee benefit expenses at Rs 1,918.37 lakh, and finance costs at Rs 364.34 lakh. Total comprehensive loss attributable to owners was Rs 364.75 lakh. Basic and diluted earnings per share on a consolidated basis were both Rs (0.75), not annualised. Paid-up equity share capital stood at Rs 5,354.90 lakh, with face value of Rs 10 per share.
Impact on Investors
The filing shows that consolidated revenue grew materially year-on-year, yet total consolidated expenses outpaced income, resulting in a pre-tax loss of Rs 557.30 lakh for Q1 FY27 against a pre-tax loss of Rs 243.20 lakh in Q1 FY26. Investors will note that the loss deepened despite the revenue increase, with employee benefit costs and other expenses both rising on an absolute basis.
Shareholders will observe that the consolidated net loss attributable to owners was Rs 401.68 lakh, while a deferred tax credit of Rs 155.62 lakh partially offset the pre-tax loss. The disclosed results are unaudited and were subjected to a limited review, which is a narrower scope of assurance than a full statutory audit, as stated in the auditor's report.
Sector / Market Context
India's pharmaceutical sector continues to be one of the largest generics exporters globally. According to the Pharmaceuticals Export Promotion Council of India, the country's pharma exports crossed USD 27 billion in FY26. Smaller formulation and drug delivery companies such as Zim Laboratories operate in a cost-competitive environment where raw material pricing and employee costs exert direct pressure on operating margins, particularly in quarters with high capacity investment activity.